NASDAQ:COLL - Collegium Pharmaceutical Stock Price, Forecast & News

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical Inc (NASDAQ:COLL) released its earnings results on Thursday, February, 27th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.10. The specialty pharmaceutical company had revenue of $74.20 million for the quarter, compared to analyst estimates of $73.31 million. Collegium Pharmaceutical had a negative return on equity of 13.14% and a negative net margin of 3.86%. The business's revenue was up 1.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.27 earnings per share. View Collegium Pharmaceutical's Earnings History.

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Collegium Pharmaceutical.

Collegium Pharmaceutical issued an update on its FY 2020 Pre-Market earnings guidance on Friday, February, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $320-340 million, compared to the consensus revenue estimate of $331.36 million.

8 equities research analysts have issued 12 month price objectives for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $43.00. On average, they expect Collegium Pharmaceutical's stock price to reach $32.29 in the next year. This suggests a possible upside of 35.9% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

News headlines about COLL stock have trended somewhat negative recently, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Collegium Pharmaceutical.

Collegium Pharmaceutical saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,310,000 shares, an increase of 13.2% from the January 15th total of 2,040,000 shares. Based on an average daily volume of 451,400 shares, the days-to-cover ratio is currently 5.1 days. Approximately 7.9% of the shares of the company are short sold. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include Agios Pharmaceuticals (AGIO), Allakos (ALLK), Myokardia (MYOK), HUTCHISON CHINA/S (HCM), Blueprint Medicines (BPMC), Axsome Therapeutics (AXSM), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Deciphera Pharmaceuticals (DCPH), Taro Pharmaceutical Industries (TARO), PPD (SDGR), Apellis Pharmaceuticals (APLS), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI) and SAGE Therapeutics (SAGE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Bausch Health Companies (BHC), Celgene (CELG), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT) and Ocular Therapeutix (OCUL).

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (13.43%), Franklin Resources Inc. (5.28%), Renaissance Technologies LLC (3.74%), Rice Hall James & Associates LLC (3.15%), Emerald Advisers LLC (2.33%) and Emerald Mutual Fund Advisers Trust (2.28%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.

COLL stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Sectoral Asset Management Inc, Massachusetts Financial Services Co. MA, Franklin Resources Inc., Charles Schwab Investment Management Inc., Oxford Asset Management LLP, J. Goldman & Co LP and Bank of America Corp DE. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer. View Insider Buying and Selling for Collegium Pharmaceutical.

COLL stock was bought by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Renaissance Technologies LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Driehaus Capital Management LLC, Janus Henderson Group PLC and Bank of Montreal Can. View Insider Buying and Selling for Collegium Pharmaceutical.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $23.75.

Collegium Pharmaceutical has a market capitalization of $796.34 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.